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adenocarcinoma of the lung
Valerie W. Rusch, MD
See related article on page 278. Despite much controversy surrounding the effectiveness of low-dose helical computed tomographic (CT) scanning for the earlydetection of lung cancer,1 the use of CT for this purpose is alreadywidespread and is rapidly changing clinical practice. Radiologistsand thoracic surgeons are confronted with the need to distinguishtiny benign pulmonary lesions from very early lung cancers and
with the challenge of determining when biopsy or resection is appropriate. However,
there are no absolute criteria for identifying very early lung cancers on CT or for
determining preoperatively the clinical and biologic behavior of an individual
tumor.
The widespread use of CT scanning is also challenging our approach to pulmo-
nary resection. Lobectomy has been the standard form of resection for most lung
cancers, based in part on a randomized trial by the Lung Cancer Study Group
showing that lesser resections were associated with a significantly higher risk of
local recurrence.2 Now the increasing diagnosis of very early lung cancers—usually
defined as T1a tumors that are 2 cm or less in size—is leading thoracic surgeons to
question whether some of these cancers could be managed appropriately by a lesser
resection. Approximately 10% to 20% of very early cancers are associated with
lymph node metastases. However, the remainder have a more indolent biologic
behavior. The risk of nodal metastases and of subsequent systemic disease is partly
but not entirely linked to the size and location of the primary tumor. The ability to
distinguish which of these small tumors will have either an aggressive or indolent
biologic behavior is critically important.
Defining which of these very early lung cancers can be managed with lesser
pulmonary resections is important not only to decrease local recurrence, minimize
operative morbidity, and preserve lung function but also because these patients
survive long enough to be at risk for a second or even a third lung cancer. The risk
of second primary lung cancers is roughly 2.5% per year. Patients who survive 5 or
more years after their initial lung cancer resection therefore face a significant
cumulative risk of second primary tumors. The greater the extent of the first
resection, the more limited are the surgical options for subsequent resections.
In this issue of the Journal, Matsugama and colleagues3 correlate the preopera-
tive high-resolution CT scan (HRCT) findings with the pathologic features and
outcomes of 96 patients who underwent resection of clinical stage Ia non–small cell
lung cancer. They find that the proportion of ground-glass opacity (GGO), defined
as a hazy increase in lung attenuation without obscuring the underlying vascular
marking, on HRCT is directly related to tumor histology, which in turn is linked to
the risk of nodal metastases and long-term survival. Specifically, all of the cancers
measuring 2 cm or less and for which the proportion of GGO to the whole tumor
shadow on CT was 50% or greater were node-negative bronchioloalveolar carci-
nomas (BACs). None of these tumors recurred after resection. The authors suggest
that the proportion of GGO on preoperative HRCT correlates with the pathologic
features of these very early cancers, predicts tumor aggressiveness and might be
useful in selecting patients for limited pulmonary resection.
As the authors point out in the “Discussion” section of their article, this analysis
is part of an emerging body of work correlating findings on imaging studies with the
pathologic features and clinical outcome of very early lung cancers.4-7 In particular,
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BACs that are characterized by a lepidic growth pattern
along the alveoli without areas of invasion present as areas
of GGO on CT, show little or no uptake on FDG–positron
emission tomographic scan, and usually have an indolent
behavior.8,9 Because areas of BAC are often seen at the
periphery of invasive adenocarcinomas, it is hypothesized
that they might represent the preinvasive form of lung
adenocarcinoma. Along with previous reports, the current
article by Matsuguma and colleagues3 certainly suggests
that limited pulmonary resection might be a correct ap-
proach to the management of small BACs. However, much
additional investigation is needed in this area. Reliable
methods are needed for characterizing and quantifying
GGO on HRCT. The findings in the current study need to be
confirmed in larger, multicenter studies. The CT character-
istics and the risk of nodal metastases for small lung cancers
that are predominantly invasive carcinomas rather than
BACs need to be fully defined. Very importantly, the mo-
lecular features of these different entities (ie, BAC, BAC
with focal invasion, and adenocarcinoma with BAC) need
to be identified and correlated with both imaging findings
and with clinical outcome.
Understanding the biology of these very early lung can-
cers could also provide insight into the behavior of some-
what more advanced tumors. For instance, the genomic or
protein abnormalities identified in very small invasive tu-
mors that have lymph node metastasis could provide clues
to the risk of systemic disease in larger tumors. This area of
investigation has become sufficiently important that it was
the subject of a 2-day meeting at the National Cancer
Institute in June 2001.10 At that meeting, it was agreed that
large multicenter studies are needed to define the imaging
characteristics, clinical and pathologic features, and molec-
ular abnormalities of very early lung cancers. Plans for such
studies are underway in several groups, including the Amer-
ican College of Surgeons Oncology Group. The results of
these studies will probably significantly alter our approach
to the diagnosis and management of very early lung cancers,
which are becoming an increasingly important part of tho-
racic surgical practice.
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